Published in Pediatr Nephrol on October 28, 2005
Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol (2014) 2.92
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2011) 1.80
Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension (2014) 1.55
Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc Disord (2012) 1.26
Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ (2012) 1.22
Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry (2012) 1.18
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics (2009) 1.02
Neurocognitive alterations in hypertensive children and adolescents. J Clin Hypertens (Greenwich) (2012) 1.00
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am (2008) 0.97
Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics (2008) 0.96
How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD. ISRN Pharmacol (2012) 0.84
Ambulatory blood pressure monitoring and renal functions in children with a solitary kidney. Pediatr Nephrol (2007) 0.84
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)? Eur Arch Psychiatry Clin Neurosci (2014) 0.84
Sudden Cardiac Death in the Young. Circulation (2016) 0.83
Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. J Cardiovasc Electrophysiol (2015) 0.82
Early postnatal exposure to methylphenidate alters stress reactivity and increases hippocampal ectopic granule cells in adult rats. Brain Res Bull (2008) 0.78
Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat (2015) 0.78
Effect of complex treatment using visual and auditory stimuli on the symptoms of attention deficit/hyperactivity disorder in children. J Exerc Rehabil (2013) 0.78
Two cases of pheochromocytoma presenting with ADHD (attention deficit hyperactivity disorder)-like symptoms. Pediatr Nephrol (2007) 0.77
Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective. Pediatr Cardiol (2013) 0.77
Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol (2016) 0.76
Adderall and cardiovascular risk: A therapeutic dilemma. Paediatr Child Health (2009) 0.75
Impact of Stimulant Medication Use on Heart Rate and Systolic Blood Pressure During Submaximal Exercise Treadmill Testing in Adolescents. J Child Adolesc Psychopharmacol (2016) 0.75
Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data. Front Pediatr (2014) 0.75
Sudden unexplained cardiac arrest in apparently healthy children: a single-center experience. Pediatr Cardiol (2012) 0.75
Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther (1971) 4.30
Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med (2003) 3.99
Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics (1996) 3.57
Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr (1997) 3.29
The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics (2004) 1.87
Ambulatory blood pressure monitoring in the pediatric patient. J Pediatr (2000) 1.47
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2005) 1.32
Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry (1993) 1.03
Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology (Berl) (1996) 0.94
24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother (2002) 0.91
Cardiovascular responses of hyperactive children to methylphenidate. JAMA (1976) 0.89
The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action. Psychopharmacologia (1975) 0.84
Endocrine and behavioral responses to methylphenidate in normal subjects. Biol Psychiatry (1986) 0.76
Transient myocardial ischemia and its relation to determinants of myocardial oxygen demand. Am J Cardiol (1990) 0.75
Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr (2007) 4.63
Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr (2007) 2.10
Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr (2002) 1.92
Ambulatory blood pressure and left ventricular mass index in hypertensive children. Hypertension (2002) 1.87
Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension (2007) 1.48
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res (2012) 0.92
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol (2006) 0.88
Cardiovascular risk factors and sequelae in hypertensive children identified by referral versus school-based screening. Hypertension (2004) 0.87
Characteristics of hypertensive children identified by primary care referral compared with school-based screening. J Pediatr (2004) 0.86
Overweight as a risk factor in children: a focus on ethnicity. Ethn Dis (2004) 0.85
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) (2008) 0.82
Psychiatric symptoms of dementia: Treatable, but no silver bullet. Cleve Clin J Med (2009) 0.75